Evidence check: CYP2C19 in the context of gut health

The role of CYP2C19 in gut health is indirect and not strongly established. CYP2C19 is a key drug-metabolizing enzyme that processes proton pump inhibitors (PPIs) like omeprazole and the antiplatelet drug clopidogrel. PPIs are commonly used for heartburn and gastric ulcers—conditions that can alter the gut microbiome. Poor metabolizers (carriers of *2 or *3 variants) have higher PPI exposure, which may increase the risk of small intestinal bacterial overgrowth (SIBO) and Clostridioides difficile infection. Additionally, CYP2C19 polymorphisms can influence the success of Helicobacter pylori eradication therapy. However, direct evidence linking CYP2C19 to gut health independent of medication is weak. Most data come from pharmacogenetic studies, not from population-based gut health research. Therefore, testing CYP2C19 in the context of gut health is only relevant if PPI or clopidogrel therapy is being considered. Without such medication, the predictive value is low. The provided context lacks specific information on CYP2C19 and gut health, so this answer is based on general pharmacogenetic knowledge.